1 reports of this reaction
2.3% of all FERROUS FUMARATE, FOLIC ACID reports
#19 most reported adverse reaction
EPISTAXIS is the #19 most commonly reported adverse reaction for FERROUS FUMARATE, FOLIC ACID, manufactured by PureTek Corporation. There are 1 FDA adverse event reports linking FERROUS FUMARATE, FOLIC ACID to EPISTAXIS. This represents approximately 2.3% of all 43 adverse event reports for this drug.
Patients taking FERROUS FUMARATE, FOLIC ACID who experience epistaxis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPISTAXIS is a less commonly reported adverse event for FERROUS FUMARATE, FOLIC ACID, but still significant enough to appear in the safety profile.
In addition to epistaxis, the following adverse reactions have been reported for FERROUS FUMARATE, FOLIC ACID:
The following drugs have also been linked to epistaxis in FDA adverse event reports:
EPISTAXIS has been reported as an adverse event in 1 FDA reports for FERROUS FUMARATE, FOLIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPISTAXIS accounts for approximately 2.3% of all adverse event reports for FERROUS FUMARATE, FOLIC ACID, making it a notable side effect.
If you experience epistaxis while taking FERROUS FUMARATE, FOLIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.